XML 47 R34.htm IDEA: XBRL DOCUMENT v3.24.3
REVENUES - Summary of Total Revenues (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Disaggregation of Revenue [Line Items]        
Total revenues $ 7,545 $ 7,051 $ 21,185 $ 20,002
U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 5,450 5,017 15,024 14,253
Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 1,167 1,040 3,459 3,146
Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 929 993 2,703 2,603
Total product sales        
Disaggregation of Revenue [Line Items]        
Total revenues 7,515 6,994 21,074 19,864
Total product sales | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 5,433 4,985 14,958 14,196
Total product sales | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 1,154 1,017 3,416 3,069
Total product sales | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 928 992 2,700 2,599
Total HIV        
Disaggregation of Revenue [Line Items]        
Total revenues 5,073 4,667 14,160 13,482
Total HIV | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 4,161 3,807 11,386 10,949
Total HIV | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 570 519 1,737 1,568
Total HIV | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 342 341 1,038 965
Biktarvy        
Disaggregation of Revenue [Line Items]        
Total revenues 3,472 3,085 9,649 8,741
Biktarvy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 2,826 2,504 7,726 7,104
Biktarvy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 375 313 1,110 920
Biktarvy | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 272 268 814 717
Descovy        
Disaggregation of Revenue [Line Items]        
Total revenues 586 511 1,496 1,475
Descovy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 534 460 1,339 1,314
Descovy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 24 25 75 75
Descovy | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 28 26 82 86
Genvoya        
Disaggregation of Revenue [Line Items]        
Total revenues 449 503 1,292 1,544
Genvoya | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 384 433 1,088 1,305
Genvoya | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 44 47 138 157
Genvoya | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 21 23 66 81
Odefsey        
Disaggregation of Revenue [Line Items]        
Total revenues 326 343 952 1,011
Odefsey | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 248 257 705 754
Odefsey | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 69 74 217 223
Odefsey | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 9 11 30 33
Symtuza - Revenue share        
Disaggregation of Revenue [Line Items]        
Total revenues 139 131 448 390
Symtuza - Revenue share | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 103 96 338 278
Symtuza - Revenue share | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 33 32 101 101
Symtuza - Revenue share | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 3 3 9 10
Other HIV        
Disaggregation of Revenue [Line Items]        
Total revenues 100 94 322 321
Other HIV | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 65 56 190 192
Other HIV | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 26 28 96 91
Other HIV | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 9 9 36 38
Total Liver Disease        
Disaggregation of Revenue [Line Items]        
Total revenues 733 706 2,302 2,093
Total Liver Disease | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 393 376 1,210 1,051
Total Liver Disease | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 132 119 411 390
Total Liver Disease | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 207 211 682 652
Sofosbuvir/Velpatasvir        
Disaggregation of Revenue [Line Items]        
Total revenues 385 377 1,266 1,159
Sofosbuvir/Velpatasvir | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 222 215 737 643
Sofosbuvir/Velpatasvir | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 67 76 230 250
Sofosbuvir/Velpatasvir | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 96 85 299 266
Vemlidy        
Disaggregation of Revenue [Line Items]        
Total revenues 232 228 699 645
Vemlidy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 126 112 338 295
Vemlidy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 11 9 33 28
Vemlidy | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 95 106 328 322
Other Liver Disease        
Disaggregation of Revenue [Line Items]        
Total revenues 116 102 337 289
Other Liver Disease | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 45 49 134 113
Other Liver Disease | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 54 33 148 112
Other Liver Disease | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 17 20 55 64
Veklury        
Disaggregation of Revenue [Line Items]        
Total revenues 692 636 1,461 1,465
Veklury | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 393 258 784 607
Veklury | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 81 65 204 227
Veklury | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 219 313 473 630
Total Oncology        
Disaggregation of Revenue [Line Items]        
Total revenues 816 769 2,446 2,167
Total Oncology | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 433 462 1,338 1,354
Total Oncology | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 291 243 828 660
Total Oncology | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 92 65 280 153
Total Cell Therapy        
Disaggregation of Revenue [Line Items]        
Total revenues 485 486 1,485 1,402
Total Cell Therapy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 208 261 683 802
Total Cell Therapy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 211 181 611 491
Total Cell Therapy | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 66 45 192 109
Tecartus        
Disaggregation of Revenue [Line Items]        
Total revenues 98 96 305 272
Tecartus | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 63 64 181 179
Tecartus | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 29 27 102 83
Tecartus | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 6 4 22 11
Yescarta        
Disaggregation of Revenue [Line Items]        
Total revenues 387 391 1,181 1,130
Yescarta | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 145 197 502 624
Yescarta | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 182 154 509 408
Yescarta | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 60 40 170 99
Trodelvy        
Disaggregation of Revenue [Line Items]        
Total revenues 332 283 960 764
Trodelvy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 226 201 655 551
Trodelvy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 80 62 217 169
Trodelvy | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 26 21 88 44
Total Other        
Disaggregation of Revenue [Line Items]        
Total revenues 201 216 705 658
Total Other | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 53 82 241 236
Total Other | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 80 72 236 224
Total Other | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 68 62 228 199
AmBisome        
Disaggregation of Revenue [Line Items]        
Total revenues 130 115 424 381
AmBisome | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 6 12 37 39
AmBisome | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 71 63 210 192
AmBisome | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 52 39 176 150
Other        
Disaggregation of Revenue [Line Items]        
Total revenues 71 101 281 277
Other | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 47 69 203 197
Other | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 8 9 26 31
Other | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 16 23 52 49
Royalty, contract and other revenues        
Disaggregation of Revenue [Line Items]        
Total revenues 30 56 111 138
Royalty, contract and other revenues | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 17 32 66 57
Royalty, contract and other revenues | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 13 23 43 77
Royalty, contract and other revenues | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues $ 1 $ 1 $ 2 $ 4